Nutriband Inc.
NTRB
NASDAQ·Healthcare·Biotechnology·Mkt cap $72.6M
$5.97
▲ +6.04%
P/E
-10.48
Mkt Cap
$72.6M
52-Wk Range
$2.80–$8.63
52-Week Range
$2.80 - $8.63
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 4.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary transdermal delivery technology platform enabling abuse-deterrent formulations
- Regulatory focus on safety addresses opioid crisis, creating favorable market conditions
- Diversified product pipeline across multiple therapeutic categories reducing development risk
- Strategic licensing partnerships with established medical device manufacturers providing credibility and resources
Bear Case
1 risk
- High volatility (beta 2.0). Larger-than-normal price swings expected.
Growth
Turning profitable
Increasing FDA approval and adoption of abuse-deterrent opioid formulations
Value
Deep value opportunity - significant discount to sector peers
Momentum
Hot
+66.8% over 3m
Quality
Stable
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying NTRB right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Sep 30, 2026
SEP 4, 2026
Revenue of $437.5K vs $437.5K expected (0.0%).
Reported EPS · last 4Q
0 of 2 beats
Q3 26
—
Q2 26
—
Revenue trend · last 8Q
—
—
+63%
+41%
-46%
-38%
-35%
-30%
Q3 24
Q4 25
Q1 25
Q2 25
Q3 25
Q4 26
Q1 26
Q2 26
$645.8K
$642.4K
$667.4K
$622.5K
$346.1K
$400.7K
$433.4K
$437.5K
Margins · last 8Q
Gross
41.6%
Profit
-201.3%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How NTRB stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.